Learn about LIBTAYO® (cemiplimab-rwlc) in the treatment of advanced NSCLC, BCC, CSCC, & as an adjuvant treatment for high-risk CSCC. Review Important Safety Info & Full Prescribing …

Oct 10, 2025 · Libtayo side effects Get emergency medical help if you have signs of an allergic reaction to Libtayo: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Seek …

Dec 9, 2024 · Libtayo is a big leap forward in fighting non-small cell lung cancer (NSCLC), especially for those at advanced stages. The EMPOWER-Lung 3 trial showed it improves lung …

LIBTAYO is indicated for the adjuvant treatment of adult patients with CSCC at high risk of recurrence [see Clinical Studies (14.1)] after surgery and radiation.

Libtayo as a monotherapy or in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with advanced non-small cell lung cancer (see Sections …

LIBTAYO (Lib-TIE-oh) is a prescription medicine used to treat people with a type of lung cancer called non–small cell lung cancer (NSCLC). LIBTAYO may be used as your first treatment …

Nov 5, 2025 · Evidence-based recommendations on cemiplimab (Libtayo) with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer in adults

Jul 5, 2019 · Overview Libtayo is a cancer medicine used in adults to treat: a type of skin cancer called cutaneous squamous cell carcinoma when the cancer is locally advanced (has spread …

On October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous …

LIBTAYO® (cemiplimab-rwlc) is a prescription medicine indicated for the treatment of adult patients with advanced NSCLC, CSCC, BCC, and as an adjuvant treatment for high-risk …